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Abstract
Background: We have previously reported the potentiation of radiotherapy by the soy isoflavone
genistein for prostate cancer using prostate tumor cells in vitro and orthotopic prostate tumor models in
vivo. However, when genistein was used as single therapy in animal models, it promoted metastasis to
regional para-aortic lymph nodes. To clarify whether these intriguing adverse effects of genistein are
intrinsic to the orthotopic prostate tumor model, or these results could also be recapitulated in another
model, we used the orthotopic metastatic KCI-18 renal cell carcinoma (RCC) model established in our
laboratory.
Methods: The KCI-18 RCC cell line was generated from a patient with papillary renal cell carcinoma.
Following orthotopic renal implantation of KCI-18 RCC cells and serial in vivo kidney passages in nude
mice, we have established a reliable and predictable metastatic RCC tumor model. Mice bearing
established kidney tumors were treated with genistein combined with kidney tumor irradiation. The effect
of the therapy was assessed on the primary tumor and metastases to various organs.
Results: In this experimental model, the karyotype and histological characteristics of the human primary
tumor are preserved. Tumor cells metastasize from the primary renal tumor to the lungs, liver and
mesentery mimicking the progression of RCC in humans. Treatment of established kidney tumors with
genistein demonstrated a tendency to stimulate the growth of the primary kidney tumor and increase the
incidence of metastasis to the mesentery lining the bowel. In contrast, when given in conjunction with
kidney tumor irradiation, genistein significantly inhibited the growth and progression of established kidney
tumors. These findings confirm the potentiation of radiotherapy by genistein in the orthotopic RCC model
as previously shown in orthotopic models of prostate cancer.
Conclusion: Our studies in both RCC and prostate tumor models demonstrate that the combination of
genistein with primary tumor irradiation is a more effective and safer therapeutic approach as the tumor
growth and progression are inhibited both in the primary and metastatic sites.
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Background
Renal cell carcinoma (RCC) incidence has increased in
recent years with approximately 38,890 new cases each
year in the United States of America [1]. The disease is
responsible for an estimated 12,840 deaths each year [1].
This increased RCC incidence may be linked to certain risk
factors including smoking, obesity, high protein diets and
hypertension [2]. Nearly half of the patients present only
with localized disease that can be treated by surgical
removal [2-4]. However, one third of the patients also
present with metastatic disease and half of the patients
treated for localized carcinomas subsequently develop
metastatic disease [2-4]. The median survival of patients
with metastases is only eight months, with a five-year sur-
vival rate of less than 10% [2-4]. Patients with metastatic
RCC frequently present with pulmonary metastases that
are poorly responsive to conventional treatment includ-
ing most chemotherapeutic drugs, hormones and radia-
tion therapy [2-5]. The treatment of metastatic disease has
been and remains a difficult clinical challenge.
To develop new and alternative therapeutic modalities for
metastatic disease and to investigate the metastatic pro-
gression and the molecular genetics of RCC, various pre-
clinical animal models were established (reviewed in ref
6). Among others, tumor xenograft models established in
immunodeficient mice by implantation of RCC cells, iso-
lated from a human tumor specimen, have been valuable
to assess responsiveness to therapy [6-9]. To investigate
the combination of radiotherapy with other treatment
modalities, we have established a xenograft metastatic
RCC tumor model by orthotopic renal implantation of a
new KCI-18 human RCC cell line in athymic nude mice.
The KCI-18 RCC model was used to study, in vivo, the
responsiveness of human RCC primary tumors and
metastases to the soy isoflavone genistein and radiation.
Genistein, the most bioactive isoflavone of soybeans, was
extensively used in cancer studies and demonstrated inhi-
bition of tumor cell growth in vitro by affecting the cell
cycle and inducing apoptosis [10]. We further showed
that genistein potentiated radiation-induced tumor cell
killing [11,12]. This was demonstrated in various human
tumor cell lines including RCC cell lines and in particular
the KCI-18 line [12]. Genistein significantly increased
tumor cell death when given prior to radiation in KCI-18
cells similar to the effect observed with the human PC-3
prostate carcinoma cell line [12]. In vivo, we previously
showed that genistein potentiated inhibition of prostate
tumor growth by radiation and controlled spontaneous
metastasis to regional para-aortic lymph nodes using two
different orthotopic metastatic prostate tumor models
[13,14]. Paradoxically, we discovered that pure genistein,
administered as a single treatment modality, promoted
increased metastasis to lymph nodes [13]. This intriguing
observation was reproduced in two independent ortho-
topic prostate tumor models, the human PC-3 xenograft
model in nude mice [13] and the mouse RM-9 model syn-
geneic in C57BL/6 mice [14] raising concerns regarding
soy-based clinical trials for cancer patients. The goals of
the current study were to investigate whether treatment
with genistein alone also promotes metastasis in the KCI-
18 orthotopic RCC model, and whether genistein com-
bined with primary tumor irradiation is an effective treat-
ment approach for RCC treatment. We found that
genistein treatment demonstrated a tendency to stimulate
the growth of the primary kidney tumor and increase the
incidence of metastasis to the mesentery lining the bowel.
In contrast when given in conjunction with kidney tumor
irradiation, genistein significantly inhibited the growth
and progression of established kidney tumors.
Methods
Establishment of KCI-18 human RCC cell line
The human renal cell carcinoma (RCC) cell line desig-
nated KCI-18 (KCI for Karmanos Cancer Institute) was
established in our laboratory from a primary renal tumor
specimen obtained from a patient with papillary RCC
(nuclear grade III/IV) [6]. Sterile tumor specimen was
delivered to the laboratory immediately after nephrec-
tomy [15]. Fatty tissue was removed and the specimen was
minced with scissors into small pieces and dissociated by
enzymatic treatment with 0.4 mg/ml collagenase type IV
(Sigma Chemical Co., St. Louis, MO) in Dulbecco's mod-
ified Eagle's medium with 4.5 g/l glucose supplemented
with 10% fetal bovine serum, 2 mM glutamine, 10 mM
HEPES buffer, 100 U/ml penicillin/streptomycin and 50
μg/ml gentamicin (Invitrogen, Carlsbad, CA). The mix-
ture was stirred overnight at room temperature and fil-
tered through a wire mesh to exclude undigested material.
The cell suspension was washed twice in Hanks' balanced
salt solution (HBSS), then viable tumor cells were sepa-
rated from dead cells by Ficoll-Hypaque density gradient
(Histopaque; Sigma) centrifugation [15]. Viable cells
obtained from the gradient interface were counted by
trypan blue exclusion and cultures of tumor cells were ini-
tiated at 0.5 × 106 cells/ml in 25-cm2 flasks [15]. The cul-
tures were incubated at 37°C in a humidified 5% CO2
incubator and split using trypsin-EDTA when confluent.
Serial in vitro passages led to the generation of KCI-18 cell
line.
Orthotopic KCI-18/IK RCC tumor model
KCI-18 cells were washed twice with HBSS and injected in
the right kidney in 5–6 week old female BALB/C nu/nu
nude immunodeficient mice (Harlan Sprague Dawley
Inc., Indianapolis, IN). Mice were anesthetized; the right
kidney was exposed through a right flank incision and
injected with 1 × 106 cells in 50 μl HBSS subcapsularly
using a 26 gauge needle, then flank wounds were closedBMC Cancer 2007, 7:4 http://www.biomedcentral.com/1471-2407/7/4
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with clips [16]. Mice were killed at various time points
and kidney tumors were removed in sterile conditions,
dissociated in single cell suspensions and cultured in vitro
to yield a new cell line designated KCI-18/IK1 (IK, intra-
kidney implantation). KCI-18/IK1 cells were reinjected in
the kidney of nude mice for additional passage in the kid-
ney as shown in Figure 1A. This cycle of in vivo kidney pas-
sage followed by in vitro culture of renal tumors was
repeated to produce new KCI-18/IK tumor cell lines (Fig-
ure 1). These KCI-18/IK cells were highly tumorigenic,
induced metastatic kidney tumors with faster kinetics, and
preserved the karyotype of the original KCI-18 cells (Fig-
ure 2, 3). Therefore, to assess the effect of therapeutic
approaches KCI-18/IK cell lines were used for kidney
implantation and a lower concentration of 5 × 105 cells in
50 μl HBSS was sufficient to produce kidney tumors. Mice
were housed and handled under sterile conditions in facil-
ities accredited by the American Association for the
Accreditation of Laboratory Animal Care. Mice received
Lab Diet # 5021 (Purina Mills, Inc., Richmond, IN), and
the animal protocol was approved by the Wayne State
University Animal Investigation Committee.
Irradiation of tumor-bearing organs
To design selective radiation exposure of the right kidney,
metallic clips were surgically placed in the kidney of anes-
thetized mice. A day later, mice were anesthetized and
immobilized in 3 jigs for radiation and positioned on an
aluminum frame mounted on the X-ray machine to
simultaneously irradiate 3 mice as previously described
[13,17]. Shielding was designed based on location of the
metallic clips by X ray radiographs (Figure 4A). A 6.4 mm
lead shield with 3 cut-outs permitting selective irradiation
of the right kidney was positioned above the three mice,
as confirmed by double exposure X-ray radiographs (Fig-
ure 4A). This allowed for selective irradiation of the right
tumor-bearing kidney and shielding the rest of the mouse
body, thus establishing the conditions for subsequent
experimental radiation treatments (Figure 4B). The radia-
tion dose to the kidney and the scattered dose to areas of
the mouse outside of the radiation field were carefully
monitored. Photon irradiation was performed with a Sie-
mens Stabilipan X-ray set (Siemens Medical Systems, Inc)
operated at 250 kV, 15 mA with 1 mm copper filtration at
a distance of 47.5 cm from the target.
Genistein treatment
Genistein (LKT Laboratories, Toronto, Canada) was dis-
solved in 0.1 M Na2CO3 and mixed with sesame seed oil
at 2:1 ratio prior to gavage and delivered orally in 0.3 ml
at a dose of 5 mg per day per mouse (250 mg/kg body
weight per day). This is a feasible and reproducible
method allowing us to control the dose administered, as
previously described [13,14]. Sesame seed oil was used to
facilitate gavage and to avoid irritation of the esophagus
by Na2CO3 [13,14]. Mice from control groups and radia-
tion-only treated groups received a mixture of 0.2 ml 0.1
M Na2CO3 and 0.1 ml sesame oil.
Experimental protocol
Before initiating treatment, a few mice were killed to mon-
itor and confirm tumor growth and size in the kidney. In
the KCI-18/IK model, small tumors are detectable by day
11 on the kidney. Established tumors were pretreated on
days 12–14 for 3 days with oral genistein then on day 15,
kidney tumors were irradiated with 8 Gy selected based on
radiation dose-titrations. A day later, genistein was
resumed and administered every other day for the dura-
tion of the experiment (Figure 4B). Seven to nine mice
were used per experimental group. Animals were killed on
day 28 after tumor cell injection to assess the effect of the
treatment on their tumors. At this time point, the tumor
burden in untreated control animals was large enough
(about 1 × 1 cm in size compared to 0.7 × 0.25 cm normal
kidney) to assess and compare the tumor growth in
treated animals. Tumor-bearing kidneys were resected and
Generation of KCI-18/IK cell lines Figure 1
Generation of KCI-18/IK cell lines. KCI-18 cells were 
injected in the kidney of nude mice. Tumor cells were iso-
lated from kidney tumors, expanded in culture and reinjected 
into mice kidneys. Three serial in vivo passages in the kidney 
resulted in new tumorigenic cell lines KCI-18/IK.
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weighed and metastases in the liver, mesentery, and lung
were assessed. Tumor nodules in liver or mesentery were
visible and were enumerated. Pulmonary metastases were
enumerated by insufflating the lungs with a 15% India ink
solution using a 21-gauge 1" i.v. catheter. The lungs were
then bleached in Fekete's solution allowing detection of
white metastatic nodules on a black lung background
[18].
Tissue preparation for histology
At completion of experiments, mice were killed and kid-
ney tumors and metastatic tumor sites including lungs,
liver and mesentery tissues were resected and processed
for histology studies. The tissues were fixed in 10% buff-
ered formalin, embedded in paraffin and sectioned. Sec-
tions were stained with hematoxylin-eosin (H&E) (Figure
2). Tissue sections were immunostained for cytokeratin
and vimentin using an avidin-biotin-immunoperoxidase
technique [13,19].
Statistical analysis
Differences in kidney tumor sizes among the various treat-
ment groups were analyzed by two-tailed unpaired t test.
Data obtained from all mice treated with genistein com-
bined with radiation were compared to data obtained
from control mice, mice treated with genistein only and
mice treated with radiation only.
Results
Establishment of xenograft metastatic orthotopic renal 
tumor model
We have established a tumor cell line designated KCI-18
RCC from a primary renal tumor specimen obtained from
a patient with papillary renal cell carcinoma (nuclear
grade III/IV). Chromosome analysis of KCI-18 RCC cell
line (passage 8 in vitro) revealed a near tetraploid chromo-
some complement with multiple clonal aberrations: 75–
85, XX, -X, add (1) (p36) x2, +2, +3, +5, +i (5) (q10), +6,
+del (7) (q11), +8, der (9;14) (q10;q10), -9, +10, +12, -
14, add (15) (q26), +16, +17, +21, +mar, ace [cp6] (Figure
2).
Following serial in vivo passages in the kidney of nude
mice, KCI-18/IK cell lines were generated (Figure 1) and
used to establish a new metastatic RCC experimental
tumor model. Cells from the KCI-18/IK lines preserved
the karyotype of the original KCI-18 RCC cell line (Figure
2). Following implantation in the kidney, KCI-18/IK cell
Chromosomal analysis of KCI-18/IK cell lines Figure 2
Chromosomal analysis of KCI-18/IK cell lines. Karyotype of KCI-18 cells showing near tetraploid chromosome comple-
ment and multiple clonal aberrations.BMC Cancer 2007, 7:4 http://www.biomedcentral.com/1471-2407/7/4
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Histology of KCI-18 kidney tumors and lung metastases Figure 3
Histology of KCI-18 kidney tumors and lung metastases. Following implantation of KCI-18/IK cells in the kidney of 
nude mice; tumors were resected at different time points and processed for histology. Kidney tumor and lung sections were 
stained with H&E. Panel A: Development of high-grade carcinoma (arrowheads) with sinusoidal vascular pattern in the kidney 
(×10). Panel B: Kidney tumor morphology distinct from normal kidney tissue tubular morphology (×25). Panel C: Kidney tumor 
consisting of cells with large pleomorphic nuclei, prominent nucleoli and abundant eosinophilic cytoplasm (×100). Panel D: Met-
astatic nodules in lung (×25). Panels E, F: Kidney tumor sections immunostained for cytokeratin (E) and vimentin (F) showing 
positive cytoplasmic staining for both markers (×50). Magnifications (×-fold) are shown for each picture.
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lines were highly tumorigenic and generated metastatic
kidney tumors in 100% of the mice. These tumors grew in
the kidney with faster kinetics than the original KCI-18
cell line shortening by 3–4 weeks the development of a
metastatic kidney tumor. Primary tumor nodules of about
0.2 cm were detectable on the kidney by day 11 after cell
injection and progressively invaded the kidney (Figure 3A,
B) reaching sizes as large as 2–2.5 cm by day 40. Metas-
tases were detectable by day 25–30 and observed mostly
in the lungs and occasionally in the liver and mesentery.
The number and frequency of metastases in the lungs
increased with time from 2–5 nodules by day 25–30 to
30–40 nodules by day 40 after cell injection. Mouse sur-
vival was about 40–45 days.
The tumor presence in the kidney was histologically con-
firmed and defined as a high grade carcinoma, highly vas-
cularized with a sinusoidal vascular pattern (Figure 3A, B).
Tumor cells were characterized by large pleomorphic
nuclei, prominent nucleoli, abundant eosinophilic cyto-
Treatment of KCI-18 kidney tumors with genistein and radiation Figure 4
Treatment of KCI-18 kidney tumors with genistein and radiation. Panel A: Design of X-ray irradiation of tumor-bear-
ing kidney. Mice in 3 jigs were positioned on an aluminum frame mounted on the X-ray machine. Exposure of the right kidney 
is confirmed by metallic clips surgically placed in the kidney and visualized in double exposure X ray radiograph while rest of 
their body was shielded with lead shield positioned above the mice. Panel B: Treatment schedule diagram. On day 12–14 after 
KCI-18 cell injection in kidney, mice were treated daily with oral genistein at 5 mg/day/mouse. On day 15, established renal 
tumors were irradiated with 8 Gy photons. One day later, genistein treatment was resumed and given every other day. On day 
28, mice were killed and tumors and metastatic tissues were resected. Panel C: Response of primary kidney tumors to radia-
tion and genistein. Weights of the tumor-bearing kidneys and their median weight, from 7–9 mice per treatment group, are 
reported in boxplot showing the range of data. Panel D: Response of mesentery metastases. Mesentery nodules were promi-
nent along the intestines and enumerated. Each dot represents the number of metastatic nodules per mouse. Panel E: 
Response of lung metastases. White metastatic nodules were enumerated on lungs insufflated with India ink and bleached as 
described in Materials and Methods. Each dot represents the number of nodules per mouse. Data from four experimental 
treatment groups are shown: mice treated with vehicle (Control), genistein only (Gen), radiation only (Rad), genistein com-
bined with radiation (Gen+Rad).
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plasm and large cytoplasmic inclusions (Figure 3C).
Tumor nodules in lungs were also clearly detectable by
histology (Figure 3D). The cytoplasm of kidney tumor
cells stained positively for cytokeratin and vimentin,
which are intermediate filaments proteins belonging to
the cell cytoskeleton (Figure 3E, F), and known to be co-
expressed by various forms of RCC [5,20]. These features
of KCI-18/IK kidney tumors resembled the histological
characteristics of the original human tumor specimen.
These findings demonstrate that we have developed a
reproducible renal cell carcinoma tumor model in nude
mice in which human tumor cells metastasize from the
primary renal tumor to the lungs in a manner that mimics
the progression of RCC in human. This model was used to
investigate RCC responsiveness to genistein combined
with radiation.
Treatment of kidney tumors with genistein and radiation
Using orthotopic metastatic prostate tumor models, we
previously showed that genistein potentiated inhibition
of prostate tumor growth by radiation and controlled
spontaneous metastasis to regional para-aortic lymph
nodes [13]. Paradoxically, we discovered that pure genis-
tein, administered as a single treatment modality, pro-
moted increased metastasis to lymph nodes [13]. This
intriguing observation was reproduced in two independ-
ent orthotopic prostate tumor models, the human PC-3
xenograft model in nude mice [13] and the mouse RM-9
model syngeneic in C57BL/6 mice (14). To test whether
treatment with genistein alone also promotes metastasis
in an orthotopic RCC model, but is effective when com-
bined with primary tumor irradiation for RCC treatment,
we used the KCI-18 RCC model. Established kidney
tumors were pre-treated with 5 mg/day oral genistein for
3 days (day 12–14) followed a day later by tumor-bearing
kidney irradiation with 8Gy using conditions described in
Materials and Methods (Figure 4A). Then, genistein treat-
ment was resumed every other day at 5 mg/day/mouse
and mice were killed on day 28 to assess the effect of ther-
apy on primary tumors and metastatic sites (Figure 4B).
This schedule and dose were selected based on our previ-
ous studies in the PC-3 prostate tumor model in vivo [13]
and in vitro findings showing that pre-treatment with gen-
istein augments radiation-induced killing both in PC-3
cells and KCI-18 cells [11,12]. In the KCI-18 tumor
model, by day 28, large tumor-bearing kidneys in control
untreated mice were observed with most of them in the
range of 500–1000 mg compared to a weight of 150–200
mg measured in normal kidneys. Compared to control
tumors, genistein treatment showed a trend in increasing
the growth of kidney tumors resulting in 800–1700 mg
weight range (Figure 4C). Radiation slowed the tumor
growth (range of 300–650 mg) compared to control
tumors but not significantly (p > 0.05) (Figure 4C). How-
ever, combination of genistein and radiation caused a sig-
nificant inhibition of kidney tumor growth (range of
270–400 mg) compared to control tumors and to genis-
tein treated tumors (p < 0.05) (Figure 4C).
Interestingly, following treatment with genistein, we
observed a greater number of suspicious nodules in the
mesentery lining the intestines that looked like tumor
nodules and were histologically confirmed to be tumor
nodules (as described in section below, see Figure 6A).
Genistein treatment caused an increase in the number and
frequency of mesentery metastases compared to untreated
control mice and to mice treated with radiation alone or
radiation combined with genistein (Figure 4D). In con-
trast, the number and frequency of lung metastases were
limited in mice treated with genistein compared to con-
trol mice (Figure 4E). Lung metastases were not observed
after radiation and genistein (Figure 4E). Liver metastases
were rare in all treatment groups.
In situ analysis of kidney tumors and metastases following 
genistein and radiation
Histological evaluation of kidney tumors, resected on day
28, was performed to determine in situ alterations induced
by genistein alone compared to genistein and radiation.
Large kidney tumors (0.9 × 1 cm) were isolated from con-
trol untreated mice and presented histologically as a
highly vascularized, high grade carcinoma with some
areas of necrosis (Figure 5A). Tumor cells had large pleo-
morphic nuclei, prominent nucleoli and abundant eosi-
nophilic cytoplasm (Figure 5B). Genistein-treated tumors
were large (1 × 1.2 cm) and presented with extensive hem-
orrhages (Figure 5C). Large areas of necrosis containing
apoptotic cells as well as atypical giant tumor cells show-
ing degenerative changes were observed (Figure 5D). Fol-
lowing radiation, tumors were a little smaller (1 × 0.6 cm)
than control tumors and contained patchy areas of fibro-
sis and necrosis infiltrated by apoptotic cells (Figure 5E),
as well as hemorrhages but not as prominent as those
induced by genistein. Residual viable tumor cells included
atypical giant tumor cells or detached rhabdoid cells with
large vacuoles (Figure 5F). In contrast to control, or genis-
tein- or radiation- treated tumors in which tumor cells
replaced completely normal kidney tissue, tumors treated
with genistein combined with radiation were focal cover-
ing 40–50% of the kidney and were surrounded by nor-
mal kidney tissue consisting of typical tubules and
glomeruli (Figure 5G). The residual tumor areas had hem-
orrhages and consisted mostly of detached rhabdoid cells
with large vacuoles and atypical giant cells with pleomor-
phic nuclei often undergoing degenerative changes (Fig-
ure 5H). Some of these tumor-bearing kidneys had small
size (0.8 × 0.4) close to that of normal kidney (0.7 × 0.25
cm).BMC Cancer 2007, 7:4 http://www.biomedcentral.com/1471-2407/7/4
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Histology of KCI-18 kidney tumors treated with genistein and radiation Figure 5
Histology of KCI-18 kidney tumors treated with genistein and radiation. Kidney tumors, resected from mice of the 
experiment described in Figure 4, were processed for histology and tumor sections were stained with H&E. The main findings 
were labeled on the prints with T for tumor, V for vessel, M for mitosis, H for hemorrhages, DG for degenerative, N for 
necrosis, A for apoptosis, F for fibrosis, DC for detached cells, R for rhabdoid cells, NKT for normal kidney tissue, IF for 
inflammatory cells and AM for abnormal mitosis. Panels A, B: Kidney tumor from control mice showing high-grade and very 
vascularized carcinoma (A, ×50) with frequent mitosis (B, ×100). Panels C, D: Kidney tumor from mice treated with genistein 
showing extensive hemorrhages (C, ×50), degenerative changes in tumor cells, apoptotic cells and areas of necrosis (D, ×100). 
Panels E, F: Irradiated kidney tumor, with areas of tumor destruction, showing fibrosis and apoptotic cells (E, ×50), focal areas 
with atypical detached rhabdoid cells (F, ×100). Panels G, H: Kidney tumor from mice treated with genistein and radiation, 
showing smaller residual tumor area adjacent to normal kidney tissue (G, ×25). The residual tumor looked hemorrhagic and 
consisted of large areas of detached rhabdoid cells, atypical giant cells with large nuclei and inflammatory cells (H, ×100). Lower 
and higher magnifications (×-fold) are presented to both show wider areas of tumor histology and focus on major findings.
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Following treatment with genistein, we observed a greater
number of nodules in the mesentery lining the intestines
(Figure 4D). Processing of sections from the bowel tissue,
for histology and H&E staining, revealed multiple tumor
nodules in mesentery fat tissue that could develop from
tumor cell migration through adipose tissue blood vessels
(Figure 6A). Staining of this tissue by immunohistochem-
istry for cytokeratin showed positive staining of tumor
cells in the nodules and the morphological characteristics
of tumor cells from the primary kidney tumor (data not
shown). The bowel looked normal and lymph nodes lin-
ing the bowel showed no involvement of tumor. In con-
trast to genistein treatment alone, following genistein
combined with radiation, no tumor nodules were
detected in the mesentery lining the bowel in most of the
mice (Figure 6B).
Discussion
We have previously reported the potentiation of radio-
therapy by the soy isoflavone genistein. This phenome-
non was demonstrated for prostate cancer using prostate
tumor cells in vitro [11,12] and orthotopic prostate tumor
models in vivo [13,14]. Genistein combined with primary
tumor irradiation caused a greater inhibition of prostate
tumors and control of lymph node metastasis than each
modality alone. These findings were reproduced in two
independent orthotopic tumor models [13,14], however,
genistein used as single therapy caused increased metasta-
sis to regional para-aortic lymph nodes [13,14]. This effect
was observed with a wide range of genistein doses, from
20 μg/day (Hillman, personal communication) up to 1–5
mg/day [13,14]. To clarify whether these intriguing
adverse effects of genistein are intrinsic to the orthotopic
prostate tumor model, these studies were repeated in the
orthotopic metastatic KCI-18 RCC model established in
our laboratory.
The KCI-18 RCC model was established from a cell line
generated by culture of cells isolated from a human papil-
lary RCC tumor specimen. Following serial renal implan-
tation of KCI-18 cells in the kidney of nude mice, we
confirmed the establishment of a reliable orthotopic RCC
experimental model. This model showed the properties of
an ideal RCC tumor model including histologically
proven carcinoma, predictable growth rate and ability to
metastasize similarly to human RCC in a reasonable time
frame [6]. The karyotype and histological characteristics
of KCI-18 cell line and kidney tumors were comparable to
those of the human primary tumor specimen from which
the cell line was produced. Like human RCC, these tumors
were highly vascularized and stained positively for cytok-
eratin and vimentin [5,20]. We showed that renal implan-
tation of the KCI-18 cell line in the kidney of nude mice
caused the formation of a primary kidney tumor that
metastasizes to the lungs, liver and mesentery; mimicking
the development and progression of metastatic RCC in
human [2,3,21]. Our studies and others demonstrate that
orthotopic models of heterotransplanted human RCC
cells are representative of human RCC progression and
preserve the karyotypic and histological characteristics of
the human primary tumor [6-9,20]. These models can be
used to study human RCC progression and metastasis and
responsiveness of human RCC tumors to treatment in
vivo.
To investigate the therapeutic effect of genistein and radi-
ation in the KCI-18 model, we first assessed KCI-18 cell
responsiveness to these modalities in vitro. KCI-18 cells
were pre-treated with genistein for 24 hr, then irradiated
and assayed in a clonogenic assay in the presence of gen-
istein [12]. KCI-18 RCC cells showed a comparable dose-
dependent inhibition of cell growth when treated with
Histology of mesentery tumor nodules following treatment  with genistein Figure 6
Histology of mesentery tumor nodules following 
treatment with genistein. Sections of the mouse bowel 
were stained with H&E. Panel A: Section of bowel (B) from 
mice treated with genistein showing tumor nodules (TN) in 
mesentery adipose tissue (AD). Panel B: Section of bowel (B) 
from mice treated with genistein and radiation and adipose 
tissue (AD) showing normal morphology of mesentery lining 
the bowel. Magnifications, ×25.
AD
TN
A
B
TN
B
B
B
B
AD
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genistein alone, but a lower response to radiation com-
pared to PC-3 cells. The combination of 15 μM genistein
with 3 Gy radiation, for KCI-18 cells, was more effective at
inhibition of colony formation (80%) than genistein
alone (45%) or radiation alone (50%) [12]. These data
confirm that RCC cell killing by radiation is also
enhanced by genistein pre-treatment as demonstrated for
PC-3 prostate cancer cells [11,12]. Based on these find-
ings, the treatment of established KCI-18 kidney tumors
with genistein alone or combined with radiation was
tested.
In the KCI-18 RCC model, treatment of kidney tumor-
bearing mice with genistein alone demonstrated a ten-
dency to augment the growth of kidney tumors compared
to control mice whereas radiation slowed the growth of
kidney tumors. In contrast, genistein given in conjunction
with tumor irradiation caused a significant inhibition in
the growth of kidney tumors. The anti-tumor activity
mediated by genistein and radiation on kidney tumors
correlates with the levels of genistein measured in the
mice blood. We have previously reported that mice
treated with 5 mg/day genistein reached serum levels of
about 30 μM compared to 0.2 μM in control mice without
apparent toxicity [13]. These levels are comparable to the
15 μM range measured in human volunteers consuming
50 mg isoflavone consisting of 40 mg of genistein and
daidzein and in other studies [22,23].
The effects of genistein combined with radiation observed
in KCI-18 kidney tumors in vivo are in agreement with our
in vitro data showing a greater inhibition of KCI-18 cell
division by the combined treatment. However, the in vivo
genistein effect of stimulating kidney tumor growth data
does not corroborate the findings of KCI-18 tumor cell
inhibition  in vitro suggesting the influence of tumor
microenvironment factors in vivo.
Interestingly, when used as a single treatment modality,
genistein also showed a trend in increasing the number
and frequency of tumor nodules in the mesentery lining
the bowel but no increase in lung metastasis was noted.
Radiation alone and combined with genistein caused lim-
ited mesentery metastasis and no lung metastases in the
majority of the mice.
These findings were confirmed by histological analysis of
the kidney tumors and tissue sections. Genistein-treated
kidney tumors showed histological changes comparable
to those observed in PC-3 prostate tumors [13], including
necrosis, apoptosis and giant tumor cells. As a result of
genistein anti-angiogenic effects [24] and the high vascu-
larity of kidney tumors, extensive hemorrhages were
observed in genistein-treated kidney tumors. In contrast
to genistein or radiation alone, tumors treated with the
combined therapy provided histological evidence for sig-
nificant inhibition of tumor growth and progression in
the kidney, with residual focal abnormal tumor cells cov-
ering only 40–50% of the kidney. These findings confirm
that genistein combined with radiation inhibit the growth
and invasion of established kidney tumors and cause
marked aberrations in tumor cells that are reminiscent of
those observed in prostate tumors [13]. Atypical giant
cells are induced by either genistein or radiation alone but
are more prominent in tumors treated with both modali-
ties and represent a slow death due to alterations in cell
division at the level of cytokinesis [13,17].
Genistein treatment showed a trend in increasing the
number and frequency of metastatic mesentery metastases
but not that of lung metastases. The mesentery tumor
nodules, located in the fat tissue lining the bowel, could
have developed from tumor cell migration through adi-
pose tissue blood vessels due to the high vascularization
of the kidney tumor. Combining genistein with tumor
irradiation controlled the genistein-induced increase of
mesentery metastases.
These data indicate that genistein treatment alone has ten-
dency to stimulate the growth of the primary kidney
tumor and to promote metastasis to proximal organs but
not to distant organs. These findings in the orthotopic
RCC model suggest that the effect of genistein on primary
tumors located in different organs may differ, as prostate
tumor growth was not increased by genistein treatment in
orthotopic prostate cancer models. However, genistein
promoted metastasis in both RCC and prostate tumor
models.
Previous animal studies have emphasized the role of gen-
istein in the prevention of prostate cancer and mammary
tumors [25-30]. In contrast, other studies showed increase
in tumor growth by genistein in experimental colon can-
cer in rats, orthotopic mouse mammary tumors and rat
prostate tumors [31-33]. Genistein induced stimulation
of kidney tumor growth in our orthotopic KCI-12 RCC is
in agreement with these studies. Our study emphasizes
the adverse effects of pure genistein when treatment is ini-
tiated on established tumors.
Clarification of the mechanism by which genistein causes
increased metastasis in proximal organs including mesen-
tery in the kidney tumor model or regional lymph nodes
in the prostate tumor model is relevant for the clinical
application of soy for cancer prevention and cancer treat-
ment. Whether additional isoflavone compounds from
the soybean (e.g., daidzein and glycitein) will protect
against increased metastasis mediated by purified genis-
tein is currently under investigation.BMC Cancer 2007, 7:4 http://www.biomedcentral.com/1471-2407/7/4
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Conclusion
The current study, using an orthotopic metastatic RCC
model, reproduced the two main findings observed in
orthotopic models of prostate cancer, i.e. potentiation of
radiotherapy by genistein and tendency of pure genistein
to increase metastasis to proximal organs, when used as a
single agent. Our studies in both RCC and prostate tumor
models demonstrate that the combination of genistein
with primary tumor irradiation is a more effective and
safer therapeutic approach as the tumor growth and pro-
gression are inhibited both in the primary site and meta-
static sites.
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